Table 3.
Correlation between statin therapy and the prevalence of CSVD at baseline in the cohort study
| Beta | Wald | OR (95% CI) | P value | |
|---|---|---|---|---|
| Prevalence of Fazekas scale ≥2 | ||||
| Model 1 | −0.783 | 4.833 | 0.457 (0.227, 0.919) | 0.028 |
| Model 2 | −0.734 | 4.478 | 0.480 (0.243, 0.947) | 0.034 |
| Model 3 | −0.734 | 4.501 | 0.480 (0.244, 0.946) | 0.034 |
| Prevalence of lacunes | ||||
| Model 1 | −0.917 | 5.533 | 0.400 (0.186, 0.858) | 0.019 |
| Model 2 | −0.842 | 4.820 | 0.431 (0.203, 0.914) | 0.028 |
| Model 3 | −0.806 | 4.449 | 0.447 (0.211, 0.945) | 0.035 |
| Prevalence ofVirchow-Robin spaces | ||||
| Model 1 | −0.614 | 4.305 | 0.541 (0.296, 0.990) | 0.038 |
| Model 2 | −0.592 | 3.916 | 0.553 (0.307, 0.994) | 0.045 |
| Model 3 | −0.578 | 3.581 | 0.561 (0.315, 0.999) | 0.048 |
| Prevalence of microbleeds | ||||
| Model 1 | 0.066 | 0.037 | 1.069 (0.544, 2.100) | 0.847 |
| Model 2 | 0.059 | 0.027 | 1.060 (0.528, 2.218) | 0.869 |
| Model 3 | 0.017 | 0.002 | 1.017 (0.516, 2.007) | 0.960 |
Model 1: Adjusted for age and sex
Model 2: model 1 + smoking, alcohol intake, history of hypertension, diabetes, and dyslipidemia; medication for hypertension, diabetes, and platelet aggregation
Model 3: model 2 + body mass index, blood pressure, fasting blood glucose, and blood lipids